Skip to content

Net Income at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$727.2M-10.1%
HRO
HarrowHROW
-$27.6M-55.2%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$104.9M-20.7%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$88.61M-38.3%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$50M-144%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$121.03M-134%

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's net income?
Kodiak Sciences Inc (KOD) reported net income of -$58.16M in Q1 2026.
How has Kodiak Sciences Inc's net income changed year-over-year?
Kodiak Sciences Inc's net income decreased by 1.2% year-over-year, from -$57.46M to -$58.16M.
What is the long-term trend for Kodiak Sciences Inc's net income?
Over 4 years (2021 to 2025), Kodiak Sciences Inc's net income has grown at a -3.7% compound annual growth rate (CAGR), from -$266.99M to -$229.97M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.